This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Cerebrovascular Disease  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Neurol. 1998;55:448.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

IN THIS issue of the ARCHIVES and the April 22/29 issue of JAMA, attention is being directed toward important, emerging areas involving the treatment, prevention, and outcome predictors of stroke. A vital area of clinical research interest is posterior circulation ischemia and stroke. Our knowledge of posterior circulation disease has not developed as completely as that of anterior circulation. Therapy for vertebrobasilar disease has remained an area of intense controversy. Caplan¹ establishes perspective and cautions us in his lead editorial in this issue when he advises us how to proceed with the latest therapeutic modality, recombinant tissue-typplasminogen activator, in patients of the kind described by Grond et al² with vertebrobasilar stroke. Of considerable interest is that Grond et al² found a favorable outcome in the majority of their patients with vertebrobasilar stroke when they were treated with intravenous recombinant tissue-type plasminogen activator and heparin within 3 hours of symptom . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?